Office of Environmental Health Hazard Assessment



Joan E. Denton, Ph.D., Director
Headquarters • 1001 I Street • Sacramento, California 95814
Mailing Address: P.O. Box 4010 • Sacramento, California 95812-4010
Oakland Office • Mailing Address: 1515 Clay Street, 16th Floor • Oakland, California 94612



June 4, 2002

Mr. Gary M. Roberts O'Donnell & Shaeffer LLP 633 West Fifth Street, Suite 1700 Los Angeles, California 90071-2007

Dear Mr. Roberts:

Thank you for your letter of April 5, 2002, requesting that the Office of Environmental Health Hazard Assessment present all statin drugs as a class of related compounds to the Carcinogen Identification Committee (CIC) for listing consideration. Consistent with the "Procedure for Prioritizing Candidate Chemicals for Consideration under Proposition 65 by the 'States Qualified Experts,'" I consulted with Dr. Thomas Mack, CIC Chair about your request. Dr. Mack agreed that there was merit to your request and, therefore, the issue of whether or not the statin drugs should be grouped as a class will be placed on the agenda for discussion at the December 2002 CIC meeting.

Thank you again for your comments and participation in this process.

Sincerely,

Joan E. Denton, Ph.D.

Jan E. Deston, Ph.D.

Director

cc: Thomas M. Mack, M.D., M.P.H.
University of Southern California
School of Medicine, MS-44
1441 Eastlake Avenue
Los Angeles, California 90033